These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16850122)

  • 1. Methodological aspects of current problems in target-based anticancer drug development.
    Yamanaka T; Okamoto T; Ichinose Y; Oda S; Maehara Y
    Int J Clin Oncol; 2006 Jun; 11(3):167-75. PubMed ID: 16850122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Problems in the current target therapy of malignancies].
    Stukov AN; Gershanovich ML; Filov VA; Imianitov EN
    Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversing resistance to targeted therapy.
    Vidal L; Attard G; Kaye S; De Bono J
    J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting kinase signaling pathways.
    Boyle SN; Koleske AJ
    Drug Discov Today; 2007 Sep; 12(17-18):717-24. PubMed ID: 17826684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Resistance to target-based therapy and its circumvention].
    Nishio K
    Nihon Rinsho; 2004 Jul; 62(7):1343-7. PubMed ID: 15283154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular targeted therapy].
    Stenner-Liewen F; Zippelius A; Pestalozzi BC; Knuth A
    Chirurg; 2006 Dec; 77(12):1118-25. PubMed ID: 17109101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular target therapy for malignant tumors].
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
    [No Abstract]   [Full Text] [Related]  

  • 9. [Kinase inhibitors and their resistance].
    Togashi Y; Nishio K
    Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
    Kim R; Toge T
    Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular targets in colon cancer].
    Borner MM
    Ther Umsch; 2006 Apr; 63(4):243-8. PubMed ID: 16689454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
    Bixby D; Talpaz M
    Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.
    Fernández A; Sanguino A; Peng Z; Crespo A; Ozturk E; Zhang X; Wang S; Bornmann W; Lopez-Berestein G
    Cancer Res; 2007 May; 67(9):4028-33. PubMed ID: 17483313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M; Sibaud V; Chevreau C; Delord JP
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uveal melanoma.
    Spagnolo F; Caltabiano G; Queirolo P
    Cancer Treat Rev; 2012 Aug; 38(5):549-53. PubMed ID: 22270078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic issues on cancer pharmacotherapy].
    Tanigawara Y
    Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From genome to drugs: where do we stand?
    Schmidt C
    J Natl Cancer Inst; 2011 Jul; 103(13):996-7. PubMed ID: 21693728
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib mesylate.
    Waller CF
    Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with antiangiogenic drugs].
    Saijo N
    Nihon Rinsho; 2010 Jun; 68(6):1007-13. PubMed ID: 20535948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.